Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 3
1947 1
1948 1
1950 5
1951 4
1952 4
1953 6
1954 2
1955 3
1956 5
1957 6
1958 3
1959 13
1960 15
1961 3
1962 7
1963 7
1964 3
1965 7
1966 3
1967 11
1968 6
1969 4
1970 13
1972 3
1973 8
1974 3
1975 8
1976 5
1977 5
1978 2
1979 6
1980 12
1981 7
1982 5
1983 5
1984 2
1985 8
1986 7
1987 13
1988 7
1989 9
1990 10
1991 12
1992 12
1993 12
1994 16
1995 20
1996 18
1997 10
1998 17
1999 18
2000 19
2001 22
2002 30
2003 21
2004 34
2005 28
2006 17
2007 30
2008 39
2009 46
2010 51
2011 42
2012 59
2013 61
2014 58
2015 64
2016 55
2017 66
2018 78
2019 86
2020 98
2021 107
2022 108
2023 101
2024 101
2025 91
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,714 results

Results by year

Filters applied: . Clear all
Page 1
IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation.
Faas M, Ipseiz N, Ackermann J, Culemann S, Grüneboom A, Schröder F, Rothe T, Scholtysek C, Eberhardt M, Böttcher M, Kirchner P, Stoll C, Ekici A, Fuchs M, Kunz M, Weigmann B, Wirtz S, Lang R, Hofmann J, Vera J, Voehringer D, Michelucci A, Mougiakakos D, Uderhardt S, Schett G, Krönke G. Faas M, et al. Among authors: fuchs m. Immunity. 2021 Nov 9;54(11):2531-2546.e5. doi: 10.1016/j.immuni.2021.09.010. Epub 2021 Oct 12. Immunity. 2021. PMID: 34644537 Free PMC article.
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. Bröckelmann PJ, et al. Among authors: fuchs m. J Clin Oncol. 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. J Clin Oncol. 2023. PMID: 36508302 Clinical Trial.
Increased β2-adrenergic signaling promotes fracture healing through callus neovascularization in mice.
Jahn D, Knapstein PR, Otto E, Köhli P, Sevecke J, Graef F, Graffmann C, Fuchs M, Jiang S, Rickert M, Erdmann C, Appelt J, Revend L, Küttner Q, Witte J, Rahmani A, Duda G, Xie W, Donat A, Schinke T, Ivanov A, Tchouto MN, Beule D, Frosch KH, Baranowsky A, Tsitsilonis S, Keller J. Jahn D, et al. Among authors: fuchs m. Sci Transl Med. 2024 Apr 17;16(743):eadk9129. doi: 10.1126/scitranslmed.adk9129. Epub 2024 Apr 17. Sci Transl Med. 2024. PMID: 38630849
The critical dynamics of hippocampal seizures.
Lepeu G, van Maren E, Slabeva K, Friedrichs-Maeder C, Fuchs M, Z'Graggen WJ, Pollo C, Schindler KA, Adamantidis A, Proix T, Baud MO. Lepeu G, et al. Among authors: fuchs m. Nat Commun. 2024 Aug 13;15(1):6945. doi: 10.1038/s41467-024-50504-9. Nat Commun. 2024. PMID: 39138153 Free PMC article.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A. Borchmann P, et al. Among authors: fuchs m. Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. Lancet Oncol. 2021. PMID: 33539742 Clinical Trial.
Reply by Authors.
Meier KM, Mata C, Kaar JL, Rensing AJ, Dudley AG, Carrasco A Jr, Drzewiecki BA, VanderBrink BA, Streur CS, Bagli DJ, Chalmers DJ, Wilcox DT, Yerkes EB, Lau GA, Vricella GJ, Hecht SL, Copp HL, Pohl HG, Franco I, Ahn J, Wiener JS, Singer JS, Long CJ, Keays MA, Daugherty MR, Fuchs ME, Austin PF, Wu CQ, Zee RS, Misseri R, Tanaka ST, Bauer SB, Rove KO. Meier KM, et al. Among authors: fuchs me. J Urol. 2024 Jul;212(1):175-176. doi: 10.1097/JU.0000000000004034. Epub 2024 May 14. J Urol. 2024. PMID: 38743826 No abstract available.
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Kunzmann V, et al. Among authors: fuchs m. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
1,714 results